Related Experiment Videos
HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic
Cord Langner1, Christof Gross, Peter Rehak
1Institute of Pathology, Medical University of Graz, Graz, Austria. cord.langner@meduni-graz.at
Urology
|January 26, 2005
Summary
HER2 protein overexpression and gene amplification are infrequent in upper urinary tract transitional cell carcinoma (TCC). Consequently, few patients may benefit from HER2-targeted therapies like Herceptin.
Area of Science:
- Oncology
- Molecular Pathology
- Uro-oncology
Background:
- Human Epidermal growth factor Receptor 2 (HER2) is a target in various cancers.
- Its role in upper urinary tract transitional cell carcinoma (TCC) requires further investigation.
- Understanding HER2 status is crucial for potential targeted therapy selection.
Purpose of the Study:
- To assess HER2 protein overexpression and gene amplification in upper urinary tract TCC.
- To correlate HER2 status with tumor grade and stage.
- To evaluate the prognostic significance of HER2 in TCC.
Main Methods:
- Analysis of 53 TCC specimens using immunohistochemistry (HercepTest).
- Fluorescence in situ hybridization (FISH) was employed for gene amplification assessment.
- Tissue microarray technique was utilized for specimen analysis.
Main Results:
- HER2 overexpression was detected in 28/53 cases, tending towards higher stages and grades.
- Weak HER2 overexpression (score 2+) correlated with angioinvasion and predicted metastasis-free survival.
- HER2 gene amplification and/or chromosome 17 polysomy were more prevalent in high-stage and high-grade tumors but lacked independent prognostic value.
Conclusions:
- HER2 overexpression and gene amplification are uncommon in upper urinary tract TCC.
- A limited subset of patients with TCC may be candidates for HER2-targeted therapies.
- Further research is needed to fully elucidate HER2's role and therapeutic potential in TCC.